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Abstract
Doublecortin and calmodulin like kinase 1 (DCLK1) is implicated in synaptic plasticity and neurodevelopment. Genetic
variants in DCLK1 are associated with cognitive traits, specifically verbal memory and general cognition. We investigated the
role of DCLK1 variants in three psychiatric disorders that have neuro-cognitive dysfunctions: schizophrenia (SCZ), bipolar
affective disorder (BP) and attention deficit/hyperactivity disorder (ADHD). We mined six genome wide association studies
(GWASs) that were available publically or through collaboration; three for BP, two for SCZ and one for ADHD. We also
genotyped the DCLK1 region in additional samples of cases with SCZ, BP or ADHD and controls that had not been whole-
genome typed. In total, 9895 subjects were analysed, including 5308 normal controls and 4,587 patients (1,125 with SCZ,
2,496 with BP and 966 with ADHD). Several DCLK1 variants were associated with disease phenotypes in the different
samples. The main effect was observed for rs7989807 in intron 3, which was strongly associated with SCZ alone and even
more so when cases with SCZ and ADHD were combined (P-value = 461025 and 461026, respectively). Associations were
also observed with additional markers in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 39UTR
(SCZ+BP). Our results suggest that genetic variants in DCLK1 are associated with SCZ and, to a lesser extent, with ADHD and
BP. Interestingly the association is strongest when SCZ and ADHD are considered together, suggesting common genetic
susceptibility. Given that DCLK1 variants were previously found to be associated with cognitive traits, these results are
consistent with the role of DCLK1 in neurodevelopment and synaptic plasticity.
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Introduction
Neuropsychological impairments are core symptoms of several
psychiatric disorders like schizophrenia (SCZ) [1,2,3], attention-
deficit/hyperactivity disorder (ADHD) [4,5], and bipolar affective
disorder (BP) [6,7]. Although genetic factors play a major role in
psychiatric disorders, only a few genes implicated in these
conditions have been identified, probably due, at least in part, to
the difficulty of identifying reliable phenotypes. It has been
suggested that the chances of identifying the genes underlying
these psychiatric disorders would be increased by studying clearly
defined endophenotypes [8] or intermediate phenotypes [7,8,9].
Several highly heritable neuro-cognitive traits have been proposed
as relevant endophenotypes, and a number of genes have been
identified that show association with these traits per se as well as
with related psychiatric disorders [10,11,12,13]. The common
associations across psychiatric phenotypes and relevant neuropsy-
chological traits could reflect a general effect of these genes on
specific neuronal functions. For instance, the potential etiological
role of the brain derived neurotrophic factor (BDNF) gene in psychiatric
disorders and cognitive traits could reflect its central role in
synaptic plasticity [14]. We hypothesised that other genes
functionally related to BDNF could also be implicated in cognition
and psychiatric disorders. We previously carried out a gene
expression analysis of BDNF-induced long-term potentiation
(LTP) of synaptic transmission in the hippocampus of live rats
[15]. We identified a set of seven genes that were up-regulated
during this treatment and were confirmed to be up-regulated in
another model of synaptic plasticity [15]. We then investigated
whether genetic variants from this set of ‘‘BDNF up-regulated’’
genes were implicated in cognitive traits. We showed that variants
in one of the seven genes, DCLK1 (doublecortin and calmodulin like
kinase 1), were significantly associated with verbal memory and IQ
scores in three independent samples of healthy adults from
Norway and Scotland [16].
DCLK1 (previously known as DCAMKL1) is a complex gene that
is translated into at least 10 proteins with two major classes of
transcripts. The long variants contain exons 1 to 20 (except for
exons 6 and 8), while the short variants contain exons 6 to 20
(except for exon 8) [17]. Two other variants are also found: the
Ca(2+)/calmodulin dependent protein kinase (CaMK)-related
peptide (exons 6 to 8; also known as CARP), and the
doublecortin-like variant (exons 1–5, 7 and 8). In rodents,
differential expression has been described, with long variants
expressed during embryogenesis and short variants in adulthood
[17]. In humans, this contrast is less pronounced; long variants are
more strongly expressed in embryos, while short variants are
predominant in adults, but all variants are seen throughout the life
span [16]. In man, the DCLK1 gene is highly expressed in the
hippocampus and in the cortices (as seen in the Human Allen
Brain Atlas, http://www.brain-map.org/). Several mouse models
have been generated to characterise the properties of the different
isoforms and domains. Knockdown models have shown that the
long DCLK1 variant is implicated in axogenesis as well as cortical
and hippocampal development [18,19,20]. Mice which over-
express the kinase domain (in the C terminal part of the protein)
showed dysregulation of the calmodulin-dependent protein kinase
activity, microtubule-associated vesicle transport and GABA-ergic
neurotransmission pathways [21]. Subsequently they displayed an
increase in anxiety behaviour [22]. Finally in a transgenic mouse
model over-expressing CARP, there was consolidation of contex-
tual fear memories [23].
The potential role of BDNF in psychiatric disorders has been
extensively studied at the gene and protein levels [24,25,26,27],
though no clear conclusion has been reached. In this study, we
aimed to investigate the effect of genetic variants in DCLK1 on
psychiatric disorders which have cognitive dysfunction as a strong
phenotypic component [1,2,3,4,5,6,7]. We chose to screen the
entire gene for association, rather than focusing on the genetic
variants associated with cognitive traits, to account for possible
allelic heterogeneity that could be due to the different samples
screened or to the different phenotypes tested. We first mined
existing datasets by extracting information from published genome
wide association studies (GWAS) of cases with SCZ, BP or ADHD,
and then added additional samples that we genotyped ourselves.
Considering that many genes have been found to have an effect
across several of these psychiatric disorders, and that these
disorders probably share a common genetic susceptibility
[28,29], we also performed cross-phenotype analyses for the
markers that were shared. We found that SNPs in DCLK1 were
associated with all three disease phenotypes. The strongest effect
was seen with a SNP in intron 3, which was very strongly
associated with SCZ, and with SCZ and ADHD considered
together.
Methods
All studies were carried out in accordance with the tenets of the
Declaration of Helsinki and were approved by the respective local
Norwegian, German, Danish and British local research ethical
committees; see [30,31,32,33,34,35,36]. Written informed consent
was given by all participants and in case of minors by their parents.
We chose to extract the data from existing genome wide
association studies (GWASs) for cases of SCZ, BP and ADHD
when available. P-values for the region covering DCLK1 610 kb,
i.e. chr13: 35,230,790-35,613,514 (NCBI build 36) were extracted
from these GWASs. In addition, samples that had not been whole-
genome typed were genotyped across the same interval. The
genotyping of these samples was performed on different platforms;
therefore, different sets of markers have been used in the different
studies.
A summary of the samples studied, the number of markers
extracted or genotyped, and the platform used is given in Table 1.
A description of the marker selection is given below.
SCZ samples
Two GWASs were mined for the DCLK1 region. The first was a
British sample described in O’Donovan et al. [34] of 479 cases
with SCZ compared to 2937 controls (the WTCCC control set)
genotyped on the Affymetrix 500 CHIP. In this sample the DCLK1
gene was covered by 85 markers. The second was a German
sample of 484 cases with SCZ and 1300 controls genotyped on the
Illumina 610 BeadChip [35]. In this sample the DCLK1 gene was
covered by 135 markers.
In addition, 129 tagSNPs covering the DCLK1 gene were
selected and included in a Golden Gate Assay to genotype the
Scandinavian Collaboration of Psychiatric Etiology (SCOPE)
sample of 481 Danish and 160 Norwegian cases with SCZ and
1088 controls (826 Danish and 262 Norwegian); see Ha˚vik et al.
[37] for a description of the assay, marker selection and quality
control protocols.
BP samples
Three BP GWASs were mined for the DCLK1 region. The first
was a British WTCCC set of 1868 cases with BP compared to
2938 controls genotyped on the Affymetrix 500 CHIP [36].
DCLK1 was covered by 107 markers. The second was a NIMH
American sample of 461 cases and 563 controls genotyped using
DCLK1 Association with Psychiatric Disorders
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35424
DNA pools with the Illumina 550 BeadChip [38]. DCLK1 was
covered by 109 markers. The third was a German sample (BoMa
sample) of 682 cases with BP and 1300 controls [30] genotyped
using the Illumina Humanmap 610 CHIPs. DCLK1 was covered
by 107 markers. After mining these GWASs, we carried out a
replication study in an additional sample of 1814 cases with BP
and 2407 controls (see Table 1 for origin details and Cichon et al.
[30] for further description of the sample). Twenty three markers
had nominal association (P-value,0.05) with BP in any of the BP
GWAS mined. Three markers (rs1750719, rs9546404 and
rs9575331) were excluded as they were in strong LD with other
markers being typed according to Hapmap data from the CEU
sample (CEPH-Utah residents with ancestry from northern and
western Europe, http://hapmap.ncbi.nlm.nih.gov/index.html.en
[39]); see Figure S1.
ADHD samples
A sample of 466 Norwegian cases and 515 controls [31] was
genotyped for markers covering the DCLK1 gene. For this sample
we chose to genotype the markers (n = 20) that had been selected
for the replication study in the BP sample. In addition, considering
that a study by Neale et al. [40] had reported a possible association
between ADHD (in a TDT [transmission/disequilibrium test]
design on 956 trios) and the marker rs1539549 (TDT corrected P-
value = 2.961025) in intron 5 of the gene [40], we chose to include
11 tagSNPs covering the LD block where this SNP was located (for
tagging SNP selection protocol see Le Hellard et al. [41]). Finally,
as we did not have information about association between the
ADHD phenotype and the markers that had shown association to
cognitive traits, we also chose to genotype the 12 markers
associated with cognition in our previous study [16]. A total of 43
markers were selected, 10 of which failed at design (4 failed at
typing, 4 had Hardy Weinberg Equilibrium P-value,0.01, and 2
had minor allele frequency ,0.05).
Later, we extracted genotypes from a GWAS of a sample of
cases with ADHD and 1300 controls [33]. This sample consists of
495 young patients with ADHD that were recruited and
phenotypically characterized in 8 psychiatric outpatient units in
Germany for children and adolescents (Aachen, Cologne, Essen,
Marburg, Homburg, Trier, Regensburg, and Wu¨rzburg). Patients
were included if they were diagnosed with ADHD according to
DSM-IV [42]. The ascertainment strategy and inclusion criteria
have been described previously [43,44]. Genome wide genotyping
for the patients was performed on Human660W-Quadv1
BeadArrays, and for the controls on HumanHap550v3 BeadAr-
rays (Illumina, San Diego, CA, USA) by the Department of
Genomics, Life & Brain Center, University of Bonn, Germany.
The same controls were used in multiple analyses (i.e. the 3
German GWASs used the same set of controls; see Table 1).
Single-sample data analysis
All samples were first analysed separately. The following criteria
were used for exclusion of markers: call rate ,90%, minor allele
frequency ,5% in controls, Hardy Weinberg Equilibrium P-
value,0.001 in controls. DNA samples which had a call rate
,90% were excluded.
The associations were tested using a logistic regression (affected
status being the outcome predicted by the genotypes, as
implemented in Helix Tree SNP & Variation Software, http://
www.goldenhelix.com/SNP_Variation/HelixTree/index.html).
The genotypes were coded as D = minor allele and d = major
allele, under an additive model DD = 0, Dd = 1 and dd = 2, in
order to perform genotypic logistic regression with sex and age as
covariates.
Phenotype-specific merged analyses and cross-
phenotype analyses
Phenotype-specific merged analyses (or mega-analyses) were
performed on the markers common between samples after quality
Table 1. Origin of the samples used either in the GWAS mining, or genotyped in the replication samples.
Phenotype Sample (reference) Application Cases Controls No. of markers Covariate code Genotyping platform
SCZ German [30] GWAS mining 484 1300* 135 2 Illumina 550v3
SCZ British [34] GWAS mining 479 2937** 85 12 Affymetrix GC500K
SCZ Danish [32] Genotyping 481 826 129 8 Illumina Golden Gate
SCZ Norwegian [32] Genotyping 160 269 129 9 Illumina Golden Gate
BP German [35] GWAS mining 682 1300* 107 2 Illumina 550v3
BP British [36] GWAS mining 1868 2937** 107 12 Affymetrix GC500K
BP American [38] GWAS mining 461 563 109 n.a. Pools Illumina 550
BP Bosnian/Serbian [35] Replication 124 115 20 1 Sequenom Massarray
BP German [35] Replication 378 768 20 3 Sequenom Massarray
BP Spanish [35] Replication 298 400 20 4 Sequenom Massarray
BP Polish [35] Replication 446 558 20 5 Sequenom Massarray
BP Romanian [35] Replication 237 234 20 6 Sequenom Massarray
BP Russian [35] Replication 331 332 20 7 Sequenom Massarray
ADHD Norwegian [31] Genotyping 466 515 35 10 Sequenom Massarray
ADHD German [33] GWAS mining 495 1300* 17 11 Illumina 660
The number of cases and controls, number of markers mined/genotyped and the genotyping technology is shown. The covariate code takes into consideration the
possible effect of country of origin and platform used in the genotypic analysis.
*Same control samples used,
**same control samples used. n.a., not applicable as the sample was not used for the merged analyses.
doi:10.1371/journal.pone.0035424.t001
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control. The genotypes of the 16 markers that showed association
in any of the mined GWAS and that had been typed in the
German BP, SCZ and ADHD GWASs were extracted along with
rs10507435, which is associated with cognitive traits [40]. In the
SCZ samples, 15 markers were analysed in the German GWAS
and the Scandinavian (SCOPE) merged genotypes as rs2051090
failed genotyping in the Scandinavian sample. In the BP samples,
the 16 markers that had been typed in the German GWAS were
used for the merged analysis of the BP samples (German GWAS
and replication sample). For ADHD, four markers (rs10507433,
rs1171092, rs1171090 and rs7994174) failed genotyping in the
Norwegian sample; thus, 12 markers were used for the merged
analysis. For cross-phenotype analyses we used the set of 11
markers that had been genotyped across all the disorders.
In these analyses, considering the low number of markers
overlapping between the British samples (genotyped on Affyme-
trix) only the samples genotyped ‘‘in house’’ or with Illumina
CHIPs were included. The analyses with the few overlapping
markers are presented in Table S8.
The cross-phenotype analyses were performed using a genotypic
logistic regression on an additive model using sex and age as
covariates. In addition, in order to control for possible confound-
ing effects of geographical location or genotyping platform we
included a correction factor which combines both the origin and
platform effects (see Table 1). For example, the German samples
that were typed on the same platform for the GWASs had the
same Country/Study factor, while the German replication sub-
sample had a different index because it was typed on another
platform.
Owing to the design of our study, in which we mined or
genotyped different sets of markers on different sets of samples
depending on availability, it is difficult to apply an appropriate
permutation-based analysis or a straightforward Bonferroni
correction factor, or a permutation test, as many of the markers
tested within the different samples or between the samples are
correlated by linkage disequilibrium. Hence, all P-values reported
in this study are un-corrected and declared significant at a nominal
threshold of P = 0.05. As a guideline to significance, we calculated
a Nyholt’s SNPSpD gene-based correction. To do this, we
downloaded genotypes for the CEU sample from HapMap release
3 (http://hapmap.ncbi.nlm.nih.gov/downloads/index.html.en
[39]) covering the whole DCLK1 genomic region. The gene was
covered by a total of 594 markers in the CEU sample. Then, using
SNPSpD (superlite version: http://gump.qimr.edu.au/general/
daleN/SNPSpDsuperlite/), we calculated that there were 340
effective independent signals across the gene [45], giving a gene-
wide significance threshold (required to keep the type I error rate
at 5%) of 0.00015. It is not possible to calculate how genetically
independent ADHD, BP and SCZ are, but a conservative
additional correction for testing 3 phenotypes would then give a
study-wide significance threshold of 0.00005 (561025).
Sequencing of conserved regions
Six regions in DCLK1 were selected for sequencing to identify
new genetic variants near the SNP rs7989807. Five of these were
regions of high inter-species conservation within 10 kb of
rs7989807, identified using the UCSC genome browser (http://
genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid = 164534183&c = chr1
&g = multiz28way). The sixth was the region around the binding site
for the REST transcription factor, which is 6.3 kb from rs7989807.
Details of the regions selected are presented in Table S9. Primer
design and sequencing were performed as described in Le Hellard
et al. [46]. Primer sequences are available upon request.
Results
Association analyses of single phenotypes
For the SCZ case control studies, we observed association with 5
markers in the GWAS: 4 in the British sample [34] and 1 in the
German sample [35] (P-values = 0.0047–0.034; Table S1 and S2).
In the Scandinavian SCOPE samples [32], 17 markers showed
association (lowest P-value = 861024 for rs9545255, see Table S3).
For the merged analysis of the German GWAS and the
Scandinavian samples, we extracted the genotypes for the 16
markers (where these had been typed) that showed evidence for
association with SCZ or BP in any of the mined GWASs. We also
extracted genotype data for rs10507435, which is strongly
associated with cognitive traits [16] and was typed in the German
GWAS. The 15 markers that were typed in both the German
GWAS and the Scandinavian sample are shown in Table 2. The
evidence for association reached the study-wide significance
threshold for the marker rs7989807 (P-value = 3.761025, odds
ratio 1.40 [95% CI: 1.20–1.63]). This association was mostly
driven by the Scandinavian cases (i.e. SCOPE) as the Scandina-
vian and German controls have the same frequencies. Four
additional markers showed stronger association (lower P-value)
and greater effect (at the odds ratio level) in the merged analysis
(see Table 2).
In the three BP GWAS that were mined [30,36,38], we
observed association with 24 markers: 10 in the German sample, 9
in the WTCCC and 5 in the NIMH sample (P-values = 0.0024–
0.049; Table S1 and S4). We selected these 24 markers for a
replication study, but excluded 3 markers that were in high LD
(r2.0.8 in the CEU HapMap sample) with other markers being
typed. Additionally, one marker failed at genotyping. Of the 20
markers analysed in the independent replication samples, two
showed association (rs7327771 P-value = 0.0053 and rs7994174 P-
value = 0.047; see Table S5), but in the opposite direction to that
of GWAS sample. In the merged analysis with the 16 markers
extracted from the German GWAS, two markers showed nominal
association (rs12874830 and rs7999483, P-value = 0.027 and
0.048, respectively; see Table 3).
For the ADHD case control studies, 33 markers were genotyped
in a Norwegian sample. No marker showed association after
quality control (Table S6). Sixteen markers were extracted from a
German GWAS of cases with ADHD and controls [33]. Three
markers were nominally significant (P-value = 0.00021–0.011;
Table S7). For the merged analysis, four of the extracted markers
were not genotyped in the Norwegian sample; thus, 12 markers
were analysed. Of these, rs7989807, rs12874830 and rs10507435
showed significant association (P-values of 0.016, 361024 and
0.036; ORs: 1.29 (1.09–1.53), 1.25(1.09–1.44) and 0.84 (0.74–
0.96) respectively; Table 4). The association reported by Neale et
al. [40] between ADHD and rs1539549 (P-value = 161025),
which is in LD with markers associated to cognitive traits [16], was
not replicated in the ADHD samples studied here (see Table 4).
Association analyses across phenotypes
Several studies have shown that psychiatric disorders such as BP
and SCZ or BP and ADHD might share common genetic
susceptibility [28,29]. In this study our hypothesis was that DCLK1
could contribute to shared susceptibility in these disorders on the
basis of its effect in cognition. We therefore tested the association
across-phenotypes. Given that we had genotypes available for all
the samples, we chose to perform mega-analyses, i.e. merging
together cases from the different studies in one analysis (we did not
look at co-morbidity) using covariates for sex and age and a
correction factor combining platform and country of origin (see
DCLK1 Association with Psychiatric Disorders
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Table 2. Association results for the SCZ cases and control samples.
Marker (position) Sample LR with covariates Minor allele (cases - controls) Odds ratio (95% CI)
rs10492555 (35607109) German 0.646 A (0.15-0.14) 1.05 (0.85–1.29)
Scand. 0.091 A (0.16-0.15) 1.11 (0.92–1.34)
German+Scand. 0.246 A (0.16-0.14) 1.09 (0.95–1.26)
rs7327771 (35577512) German 0.162 A (0.06-0.05) 1.24 (0.91–1.69)
Scand. 0.011* A (0.06-0.05) 1.28 (0.95–1.72)
German+Scand. 0.033* A (0.06-0.05) 1.25 (1.01–1.55)
rs7994174 (35573018) German 0.057 A (0.09-0.07) 1.28 (0.99–1.67)
Scand. 0.013* A (0.09-0.07) 1.36 (1.07–1.75)
German+Scand. 0.0021* A (0.09-0.07) 1.32 (1.11–1.58)
rs7989807 (35523089) German 0.012* T (0.13-0.10) 1.34 (1.07–1.68)
Scand. 0.00058* T (0.14-0.10) 1.43 (1.16–1.76)
German+Scand. 0.000037* T (0.14-0.10) 1.40 (1.20–1.63)
rs12874830 (35470040) German 0.377 G (0.20-0.19) 1.08 (0.90–1.30)
Scand. 0.109 G (0.20-0.19) 1.06 (0.90–1.26)
German+Scand. 0.255 G (0.20-0.19) 1.08 (0.95–1.22)
rs1171090 (35408728) German 0.892 A (0.26-0.26) 0.98 (0.83–1.16)
Scand. 0.226 A (0.27-0.26) 1.05 (0.89–1.22)
German+Scand. 0.736 A (0.27-0.26) 1.02 (0.91–1.14)
rs1171092 (35407728) German 0.874 A (0.26-0.26) 0.98 (0.83–1.16)
Scand. 0.199 A (0.27-0.25) 1.07 (0.91–1.25)
German+Scand. 0.626 A (0.26-0.26) 1.02 (0.91–1.15)
rs7990263 (35359216) German 0.397 A (0.35-0.34) 1.06 (0.91–1.24)
Scand. 0.909 A (0.32-0.31) 1.05 (0.91–1.22)
German+Scand. 0.270 A (0.34-0.33) 1.04 (0.94–1.16)
rs1750921 (35350069) German 0.271 T (0.23-0.25) 0.91 (0.76–1.08)
Scand. 0.791 T (0.24-0.23) 1.04 (0.89–1.22)
German+Scand. 0.720 T (0.24-0.24) 0.97 (0.86–1.09)
rs1926452 (35342937) German 0.990 A (0.16-0.16) 0.99 (0.81–1.22)
Scand. 0.324 A (0.15-0.14) 1.07 (0.88–1.29)
German+Scand. 0.587 A (0.15-0.15) 1.03 (0.89–1.18)
rs10507435 (35338996) German 0.723 G (0.27-0.27) 1.02 (0.87–1.21)
Scand. 0.810 G (0.25-0.25) 1.02 (0.87–1.20)
German+Scand. 0.602 G (0.26-0.26) 1.01 (0.90–1.13)
rs10507433 (35322698) German 0.509 T (0.19-0.20) 0.94 (0.78–1.13)
Scand. 0.733 T (0.18-0.18) 0.98 (0.82–1.17)
German+Scand. 0.583 T (0.18-0.19) 0.95 (0.83–1.07)
rs9545424 (35281264) German 0.250 A (0.13-0.12) 1.13 (0.91–1.41)
Scand. 0.029* A (0.15-0.12) 1.22 (1.00–1.49)
German+Scand. 0.026* A (0.14-0.12) 1.18 (1.02–1.37)
rs7999483 (35251437) German 0.147 C (0.12-0.10) 1.18 (0.94–1.48)
Scand. 0.021* C (0.13-0.11) 1.24 (1.01–1.53)
German+Scand. 0.013* C (0.13-0.11) 1.22 (1.05–1.42)
rs9545297 (35239668) German 0.389 G (0.15-0.14) 1.09 (0.89–1.34)
Scand. 0.0080* G (0.17-0.14) 1.32 (1.09–1.59)
German+Scand. 0.0062* G (0.16-0.14) 1.22 (1.06–1.40)
Analyses are presented for both the allelic regression and the genotypic regression for which the genotypes were recoded under an additive genotypic model; age, sex
and country/study were used as covariates. The German sample consists of 484 cases and 1300 controls. The Scandinavian SCOPE (Scandinavian Collaboration on
Psychiatric Etiology) sample (Scand.) consists of 641 cases and 1086 controls and was created by merging the Danish and Norwegian samples, which were shown
previously to be similar [32,41]. The 15 markers that were typed or extracted in the 2 samples are presented (1125 cases and 2386 controls); see Tables S2 and S3 for
results from all markers in each sample. In Tables 2, 3, 4, and 5, the position (hg18, NCBI36) of each marker is given below its rsID, the minor alleles and their frequencies
in cases and controls are given, together with the odds ratio, the 95% confidence interval and the genotype success (call rate).
*indicates significant P-values (,0.05).
doi:10.1371/journal.pone.0035424.t002
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Table 3. Association results for the BP cases and control samples.
Marker (position) Sample LR with covariates Minor allele (cases - controls) Odds ratio (95% CI)
rs10492555 (35607109) German GWAS 0.717 T (0.15-0.14) 1.03 (0.86–1.24)
Replication 0.388 T (0.16-0.15) 1.05 (0.94–1.18)
All 0.351 T (0.16-0.15) 1.05 (0.95–1.16)
rs7327771 (35577512) German GWAS 0.029* T (0.07-0.05) 1.35 (1.03–1.76)
Replication 0.0053* T (0.04-0.06) 0.75 (0.61–0.91)
All 0.297 T (0.05-0.05) 0.90 (0.77–1.06)
rs7994174 (35573018) German GWAS 0.032* T (0.09-0.07) 1.29 (1.02–1.63)
Replication 0.047* T (0.07-0.08) 0.82 (0.70–0.97)
All 0.691 T (0.07-0.08) 0.95 (0.83–1.09)
rs7989807 (35523089) German GWAS 0.088 A (0.12-0.10) 1.20 (0.97–1.48)
Replication 0.864 A (0.11-0.11) 1.01 (0.88–1.16)
All 0.283 A (0.11-0.11) 1.07 (0.96–1.20)
rs12874830(35470040) German GWAS 0.025* C (0.21-0.19) 1.19 (1.02–1.40)
Replication 0.260 C (0.21-0.20) 1.06 (0.95–1.18)
All 0.027* C (0.21-0.19) 1.10 (1.01–1.20)
rs1171090 (35408728) German GWAS 0.043* C (0.29-0.26) 1.16 (1.00–1.34)
Replication 0.324 C (0.27-0.27) 0.95 (0.86–1.05)
All 0.771 C (0.27-0.27) 1.01 (0.93–1.10)
rs1171092 (35407728) German GWAS 0.046* C (0.29-0.26) 1.15 (1.00–1.34)
Replication 0.496 C (0.27-0.27) 0.97 (0.88–1.07)
All 0.596 C (0.27-0.27) 1.02 (0.94–1.11)
rs7990263 (35359216) German GWAS 0.874 T (0.34-0.34) 0.98 (0.86–1.13)
Replication 0.894 T (0.35-0.35) 0.99 (0.91–1.09)
All 0.852 T (0.35-0.35) 1.00 (0.92–1.07)
rs2051090 (35352193) German GWAS 0.509 T (0.45-0.46) 0.95 (0.84–1.09)
Replication 0.941 T (0.45-0.45) 1.01 (0.92–1.10)
All 0.723 T (0.45-0.45) 0.99 (0.92–1.06)
rs1750921 (35350069) German GWAS 0.028* T (0.22-0.25) 0.84 (0.72–0.98)
Replication 0.702 T (0.21-0.21) 1.01 (0.91–1.13)
All 0.333 T (0.22-0.22) 0.94 (0.86–1.03)
rs1926452 (35342937) German GWAS 0.049* A (0.13-0.16) 0.83 (0.69–1.00)
Replication 0.951 A (0.13-0.13) 1.00 (0.88–1.13)
All 0.234 A (0.13-0.14) 0.93 (0.84–1.03)
rs10507435 (35338996) German GWAS 0.161 C (0.25-0.27) 0.89 (0.77–1.04)
Replication 0.532 C (0.23-0.24) 0.96 (0.87–1.07)
All 0.182 C (0.24-0.25) 0.93 (0.85–1.01)
rs10507433 (35322698) German GWAS 0.558 A (0.19-0.20) 0.95 (0.80–1.12)
Replication 0.218 A (0.19-0.18) 1.08 (0.95–1.21)
All 0.514 A (0.19-0.19) 1.02 (0.93–1.12)
rs9545424 (35281264) German GWAS 0.049* T (0.14-0.12) 1.20 (0.99–1.46)
Replication 0.913 T (0.12-0.12) 0.99 (0.87–1.13)
All 0.222 T (0.12-0.12) 1.05 (0.94–1.17)
rs7999483 (35251437) German GWAS 0.015* G (0.13-0.10) 1.27 (1.04–1.56)
Replication 0.475 G (0.10-0.10) 1.03 (0.90–1.19)
All 0.048* G (0.11-0.10) 1.10 (0.98–1.23)
rs9545297 (35239668) German GWAS 0.028* C (0.16-0.14) 1.22 (1.02–1.46)
Replication 0.714 C (0.14-0.14) 1.01 (0.89–1.14)
All 0.126 C (0.15-0.14) 1.07 (0.97–1.18)
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Analyses are presented for both the allelic regression and the genotypic regression for which the genotypes were recoded under an additive genotypic model; age, sex
and country/study were used as covariates. The German sample consists of 682 cases and 1300 controls; the replication sample consists of 1814 cases and 2407 controls.
The 16 markers that were typed or extracted in the 2 samples are presented (2496 cases and 3707 controls); see Tables S4 and S5 for results from all markers in each
sample.
*indicates significant P-values (,0.05).
doi:10.1371/journal.pone.0035424.t003
Table 3. Cont.
Table 4. Association results for the ADHD cases and control samples.
Marker (position) Sample LR with covariates Minor allele (cases - controls) Odds ratio (95% CI)
rs10492555 (35607109) NO ADHD 0.168 A (0.18-0.15) 1.20 (0.94–1.52)
GE ADHD 0.766 A (0.15-0.14) 1.05 (0.86–1.29)
NO+GE 0.147 A (0.16-0.14) 1.15 (0.98–1.33)
rs7327771 (35577512) NO ADHD 0.497 A (0.07-0.06) 1.13 (0.80–1.60)
GE ADHD 0.201 A (0.06-0.05) 1.19 (0.88–1.62)
NO+GE 0.165 A (0.06-0.05) 1.21 (0.97–1.52)
rs7989807 (35523089) NO ADHD 0.098 T (0.15-0.12) 1.24 (0.96–1.61)
GE ADHD 0.085 T (0.12-0.10) 1.22 (0.97–1.53)
NO+GE 0.016* T (0.13-0.10) 1.29 (1.09–1.53)
rs12874830 (35470040) NO ADHD 0.283 G (0.20-0.18) 1.13 (0.90–1.42)
GE ADHD 0.00022* G (0.24-0.19) 1.38 (1.16–1.65)
NO+GE 0.00029* G (0.22-0.18) 1.25 (1.09–1.44)
rs7990263 (35359216) NO ADHD 0.107 A (0.30-0.33) 0.85 (0.70–1.03)
GE ADHD 0.714 A (0.35-0.34) 1.02 (0.88–1.20)
Merged 0.481 A (0.32-0.34) 0.93 (0.83–1.05)
rs2051090 (35352193) NO ADHD 0.991 T (0.49-0.49) 0.99 (0.83–1.18)
GE ADHD 0.556 T (0.46-0.46) 1.01 (0.87–1.17)
NO+GE 0.848 T (0.48-0.47) 1.03 (0.92–1.15)
rs1750921 (35350069) NO ADHD 0.310 T (0.26-0.24) 1.11 (0.91–1.37)
GE ADHD 0.422 T (0.24-0.25) 0.91 (0.77–1.08)
NO+GE 0.982 T (0.25-0.25) 0.99 (0.87–1.12)
rs1926452 (35342937) NO ADHD 0.786 A (0.14-0.14) 1.01 (0.78–1.30)
GE ADHD 0.276 A (0.14-0.16) 0.88 (0.72–1.09)
NO+GE 0.365 A (0.14-0.15) 0.92 (0.79–1.07)
rs10507435 (35338996) NO ADHD 0.542 G (0.21-0.23) 0.90 (0.72–1.12)
GE ADHD 0.077 G (0.24-0.27) 0.86 (0.73–1.02)
NO+GE 0.036* G (0.23-0.26) 0.84 (0.74–0.96)
rs9545424 (35281264) NO ADHD 0.055 A (0.10-0.13) 0.75 (0.57–1.00)
GE ADHD 0.134 A (0.15-0.12) 1.26 (1.02–1.55)
NO+GE 0.798 A (0.12-0.12) 1.01 (0.86–1.20)
rs7999483 (35251437) NO ADHD 0.189 C (0.10-0.12) 0.82 (0.62–1.09)
GE ADHD 0.287 C (0.12-0.10) 1.20 (0.96–1.51)
NO+GE 0.809 C (0.11-0.11) 1.03 (0.87–1.23)
rs9545297 (35239668) NO ADHD 0.379 G (0.12-0.13) 0.88 (0.67–1.14)
GE ADHD 0.185 G (0.16-0.14) 1.20 (0.98–1.47)
NO+GE 0.521 G (0.14-0.14) 1.04 (0.89–1.22)
Analyses are presented for both the allelic regression and the genotypic regression for which the genotypes were recoded under an additive genotypic model; age, sex
and country/study were used as covariates. The Norwegian (NO) sample consists of 466 cases and 515 controls; the German (GE) sample consists of 500 cases and 1300
controls. The 12 markers that were typed or extracted in the 2 samples are presented (966 cases and 1815 controls); see Tables S6 and S7 for results from all markers in
each sample.
*indicates significant P-values (,0.05).
doi:10.1371/journal.pone.0035424.t004
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Methods and Table 1). Given that the British BP and SCZ samples
have few markers in common with the other samples, the data
from the two British samples are not included in the results
reported below or in Tables 2, 3, 4, 5, but are available in Table
S1. The set of 16 markers extracted from the German GWASs for
SCZ, BP and ADHD was used to perform cross-phenotype
analyses. Fifteen of the 16 markers were typed in the SCZ and BP
samples (one marker failed in the SCZ Scandinavian sample), and
11 of the 16 markers were typed in the ADHD sample.
The overall minimum P-value observed was 461026 for the
marker rs7989807 (OR: 1.32 [1.17–1.49]) in the ADHD and SCZ
merged analysis. Although this P-value fails to reach the accepted
genome-wide significance threshold of 5610-8, it does reach the
study-wide significance threshold (see Table 5). The same marker
was already strongly associated in the SCZ (merged) sample; it did
not reach significance in the ADHD sample alone but it did show
an effect in the same direction. The increased evidence of
association of this marker (or a genetic variant with which it is in
LD) comes from the increased the sample size when ADHD and
SCZ are combined.
In addition, different markers in the gene show association with
different phenotypes (SCZ, BP or ADHD individually, or in
different combinations) suggesting either type I or type II errors or
allelic heterogeneity (see Table 5).
In order to test for the effect that can be explained by the
association with rs7989807, we performed conditional regression
in the different samples using rs7989807 as a covariate (in addition
to country/study, gender and age covariates). In the
ADHD+BP+SCZ, the BP+ADHD and the ADHD+SCZ analyses,
only rs12874830, in intron 3, remained significant (P-val-
ues = 0.013, 0.002 and 0.02, respectively; Table 5). Most of the
association in these analyses can be attributed to an effect picked
up by rs7989807, while the rs12874830 association signal might
reflect an additional signal in this region. For BP+SCZ, rs9545297
(in the 39UTR) and rs7999483 (in intron 19) remained nominally
significant (P-values = 0.024 and 0.019, respectively; Table 5),
which suggests that there could also be another, weaker, signal of
association in this region.
Screening for additional causative genetic variants in a
conserved region around rs7989807
The major signal of association observed in this study is located
in intron 3 for SCZ and ADHD combined. Considering that
intron 3 is large (164 kb) and that long transcripts of the gene are
probably controlled by a CpG-rich intronic promoter (as seen on
the UCSC genome browser http://genome.ucsc.edu/cgi-bin/
hgGateway), we hypothesised that this intron could harbour
regulatory regions controlling the expression of the gene and that
the association observed could reflect the effect of other genetic
variants (in linkage disequilibrium with rs7989807) in these
regulatory regions. We sequenced 5 regions of high inter-species
conservation, which potentially contain regulatory elements,
located within 10 kb of rs7989807 (Table S9). We also sequenced
a region located 6.3 kb from rs7989807 (chr13:35529882-
35528777, hg18; Table S9) containing a known binding site for
the transcriptional repressor REST, which regulates a large
network of neuronal genes [47]. The sequencing was performed
on genomic DNA from 12 individuals with SCZ, 4 carrying each
of the AA, AG or GG rs7989807 genotypes. We identified 16
variants in these sequences, 10 previously reported in dbSNP and
6 not previously reported (but now submitted; http://www.ncbi.
nlm.nih.gov/projects/SNP/). None of the 16 variants was in
linkage disequilibrium with rs7989807 (see Table S10); hence none
was potentially causative for the association observed.
In addition, we screened eQTL databases: the Genotype Tissue
Expression eQTL browser (http://www.ncbi.nlm.nih.gov/gtex/
GTEX2/gtex.cgi), the eqtl browser at the University of Chicago
(http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/) and seeQTL
(http://gbrowse.csbio.unc.edu/cgi-bin/gb2/gbrowse/seeqtl/)
[48] for the SNPs associated in our cross-phenotype tests (i.e SNPs
with P-value,0.05 in Table 5). None of these SNPs were present
in these databases.
Discussion
In this study we show that genetic variants in DCLK1 are
associated across psychiatric disorders. In our previous study, we
demonstrated association across neuropsychological functions
[16]. This points to a potential effect of these DCLK1 variants
on central neuronal functions. Figure 1 summarises the results
from this study on psychiatric disorders and from our previous
studies of association to cognitive traits [16].
In these two studies, we observed association of several markers
in the gene with the different phenotypes. It is plausible that
several variants in the gene could have an influence on the
different phenotypes at different effect sizes. Similar observations
of trait-associated allelic heterogeneity have been reported for
genes associated with cognition and psychiatric disorders. For
instance DISC1, which was first reported as a translocated gene
segregating with SCZ in a Scottish family [49], has since been
associated in several samples with SCZ, BP or with cognitive
abilities such as working memory (for review see Chubb et al.
[10]). However, the DISC1 genetic variants that show the strongest
associations vary often within and between traits [10,50]. Hennah
et al. [51] have shown that some of the heterogeneity could be
diminished by ‘‘locking’’ these analyses on specific markers using
conditional regression;, nevertheless, it seems that several genetic
variants in DISC1 are associated at different levels with several
traits [10,50]. Similar allelic heterogeneity for DCLK1 could
explain why some variants in intron 3 seem to be more strongly
associated with SCZ and ADHD, while additional variants in the
39 of the gene show association with BP, and variants in intron 5
are associated with cognitive traits. At present we cannot exclude
the possibility that these variations in associated markers are due to
type I or type II errors. Overall, when we consider cognitive and
psychiatric traits, it seems that there are 3 main regions of
association in the gene: i) intron 3, which shows the strongest
signal in the SCZ+ADHD cross–phenotype analysis but is also
associated with IQ and memory; ii) intron 5/6, which essentially
shows association with memory and IQ; iii) intron 19 and the
39UTR, which show nominal association across psychiatric
disorders and IQ and memory. In order to distinguish the true
signals in these regions and their association to the different
phenotypes, we will need to carry out high-density genotyping (or
imputation) of the gene in large samples of individuals, and
probably perform alternative analyses such as conditional
regression or haplotype analyses. Hopefully, with the release of
large imputed datasets as planned by the Psychiatric GWAS
consortium [52] for several traits, it will be possible to get a better
coverage of the DLCK1 region.
As shown in Figure 1, the major signal of association observed
in this study is located in intron 3 for SCZ and ADHD. Additional
signals of association are also observed in introns 4 and 5 and in
the 39UTR. The available information from eQTL databases is
rather limited for this region and our attempt to identify potential
regulatory variants by sequencing within intron 3 did not identify
any convincing candidates. Regulation of the long and short forms
of the transcript is likely to be very complex, as shown by their
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Table 5. Association analyses across ADHD, SCZ and BP phenotypes.
Marker (position) Sample LR with covariates Minor allele (cases - controls) Odds ratio (95% CI)
rs10492555 (35607109) ADHD+BP 0.153 A (0.16-0.15) 1.06 (0.97–1.16)
ADHD+SCZ 0.058 A (0.16-0.15) 1.10 (0.99–1.23)
BP+SCZ 0.167 A (0.16-0.15) 1.05 (0.97–1.15)
ADHD+BP+SCZ 0.071 A (0.16-0.15) 1.06 (0.98–1.15)
rs7327771 (35577512) ADHD+BP 0.616 A (0.05-0.05) 0.96 (0.84–1.10)
ADHD+SCZ 0.011* A (0.06-0.05) 1.23 (1.04–1.45)
BP+SCZ 0.918 A (0.05-0.05) 1.00 (0.87–1.14)
ADHD+BP+SCZ 0.634 A (0.05-0.05) 1.03 (0.91–1.16)
rs7989807 (35523089) ADHD+BP 0.052 T (0.12-0.11) 1.10 (1.00–1.22)
ADHD+SCZ 0.0000042* T (0.13-0.10) 1.32 (1.17–1.49)
BP+SCZ 0.0021* T (0.12-0.11) 1.15 (1.05–1.27)
ADHD+BP+SCZ 0.00026* T (0.12-0.11) 1.16 (1.06–1.26)
rs12874830 (35470040) ADHD+BP 0.0011* G (0.21-0.19) 1.13 (1.05–1.23)
ADHD+SCZ 0.0034* G (0.21-0.19) 1.15 (1.04–1.27)
BP+SCZ 0.035* G (0.21-0.19) 1.08 (1.00–1.17)
ADHD+BP+SCZ 0.0027* G (0.21-0.19) 1.11 (1.04–1.19)
rs7990263 (35359216) ADHD+BP 0.544 A (0.34-0.35) 0.97 (0.91–1.04)
ADHD+SCZ 0.793 A (0.33-0.33) 1.01 (0.93–1.10)
BP+SCZ 0.548 A (0.34-0.34) 1.02 (0.95–1.08)
ADHD+BP+SCZ 0.984 A (0.34-0.34) 1.00 (0.94–1.06)
rs1750921 (35350069) ADHD+BP 0.732 T (0.22-0.23) 0.98 (0.91–1.06)
ADHD+SCZ 0.991 T (0.24-0.24) 0.99 (0.91–1.09)
BP+SCZ 0.511 T (0.22-0.23) 0.97 (0.9–1.05)
ADHD+BP+SCZ 0.988 T (0.23-0.23) 0.99 (0.93–1.06)
rs1926452 (35342937) ADHD+BP 0.329 A (0.13-0.14) 0.95 (0.87–1.04)
ADHD+SCZ 0.907 A (0.15-0.15) 0.99 (0.89–1.11)
BP+SCZ 0.718 A (0.14-0.14) 0.98 (0.90–1.07)
ADHD+BP+SCZ 0.769 A (0.14-0.14) 0.98 (0.91–1.06)
rs10507435 (35338996) ADHD+BP 0.084 G (0.23-0.25) 0.93 (0.86–1.00)
ADHD+SCZ 0.345 G (0.25-0.25) 0.96 (0.87–1.05)
BP+SCZ 0.524 G (0.24-0.25) 0.97 (0.91–1.05)
ADHD+BP+SCZ 0.266 G (0.24-0.25) 0.96 (0.90–1.03)
rs9545424 (35281264) ADHD+BP 0.389 A (0.12-0.12) 1.03 (0.94–1.14)
ADHD+SCZ 0.131 A (0.13-0.12) 1.10 (0.97–1.23)
BP+SCZ 0.054 A (0.13-0.12) 1.09 (0.99–1.19)
ADHD+BP+SCZ 0.125 A (0.13-0.12) 1.07 (0.98–1.16)
rs7999483 (35251437) ADHD+BP 0.129 C (0.11-0.10) 1.07 (0.97–1.19)
ADHD+SCZ 0.079 C (0.12-0.11) 1.12 (0.99–1.26)
BP+SCZ 0.0071* C (0.12-0.10) 1.13 (1.03–1.25)
ADHD+BP+SCZ 0.022* C (0.11-0.10) 1.10 (1.01–1.21)
rs9545297 (35239668) ADHD+BP 0.177 G (0.15-0.14) 1.06 (0.97–1.16)
ADHD+SCZ 0.027* G (0.15-0.14) 1.13 (1.01–1.27)
BP+SCZ 0.0093* G (0.15-0.14) 1.11 (1.02–1.21)
ADHD+BP+SCZ 0.024* G (0.15-0.14) 1.09 (1.01–1.18)
For ADHD+BP, 3462 cases versus 4222 controls were analyzed; for ADHD+SCZ, 3621 cases versus 4793 controls were analyzed; for BP+SCZ, 2092 cases versus 2901
controls were analyzed; for ADHD+BP+SCZ, 4587 cases versus 5308 controls were analyzed. The 11 markers typed in all the samples are presented.
*indicates significant P-values (,0.05).
doi:10.1371/journal.pone.0035424.t005
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complex pattern of expression in the mouse and human brains (see
the Atlas of the Developing Brain: http://www.brainspan.org). It
is probable that several regulatory elements or non coding RNAs
in the region are involved in this complex regulation. For instance
several signals of histone modification are present in intron 3 in the
vicinity of rs7989807 (as seen on the UCSC genome browser,
http://genome.ucsc.edu), and several micro RNA binding sites are
predicted in the 39 UTR of DCLK1 (as seen in the Target Scan
browser http://www.targetscan.org). In addition, the 59 exon of
an overlapping gene (MAB21L1) was recently predicted to be
located within intron 3 of DCLK1. Thus, it is difficult at this stage
to draw conclusions or even speculate on what biological effects
could be associated with the genetic variants implicated in the
present study. We are currently working on further characterisa-
tion of the expression and functions of the DCLK1 transcripts. It is
also interesting to note that a deletion encompassing DCLK1 and
neighbouring genes was reported in a patient suffering from
autism and language deficit by Smith et al. in 2002 [53]. This adds
to the evidence that genetic variants in this region may be
implicated in general susceptibility to mental disorders. However
more work is warranted to understand which genes and variants
are responsible.
It is now rather well documented that SCZ and BP probably
share some genetic susceptibility [54,55]. Co-morbidity and shared
etiological factors have also been reported for ADHD and BP [5].
Though clinical or familial overlap between SCZ and ADHD has
not been widely reported, and studies looking at genetic overlap
between these disorders are rare, some groups have nevertheless
reported co-segregation of these two disorders in families [56,57].
Recently, several studies looking at copy number variants (CNVs)
have shown that ADHD and SCZ do share several rare CNV
variants [58,59,60]. Our results present for the first time a gene in
which common variants show association with SCZ and ADHD
and to a lesser extent with BP. SCZ and ADHD are both
characterised by severe cognitive deficits, mostly in attention and
general cognition, and they both manifest early in development,
which is in accordance with an effect of DCLK1 on neurodevel-
opment and cognitive phenotypes. Further cross-phenotype
studies on large samples from the Psychiatric GWAS Consortium
(PGC) may help to identify additional genes showing similar
patterns of effects across phenotypes, thus helping us understand
how these diagnoses overlap at the genetic and symptom level. It
will also be interesting to integrate these data with results from
GWASs of cognitive traits.
Supporting Information
Figure S1 Selection of markers for replication and
genotype extraction from GWASs. Heatmap of linkage
disequilibrium (LD) between the markers showing association
with BP or SCZ at the GWAS mining stage, taken from the
HapMap CEU sample (http://hapmap.ncbi.nlm.nih.gov) [39],
Figure 1. Association of DCKL1 genetic variants with psychiatric and cognitive traits. Markers are ordered from 59 to 39 of the gene, anti-
sense to the reference sequence. A. Representation of the genomic region covered and of 6 DCLK1 transcripts (from top to bottom: DCL, CARP, 2
short variants and 2 long variants). In addition to alternative start sites, the transcripts can be alternatively spliced for part of exon 9, for exon 19 and
in the 39UTR. B. All markers showing nominal association to psychiatric traits in this study or to cognitive traits in our previous study [16] are
displayed. Color code: yellow, P-value between 0.05 and 0.001; orange, P-value between 0.001 and 0.0001; red, P-value,0.0001; white, P-value.0.05;
grey, marker not tested in this sample. The markers used in the cross-phenotype analyses are highlighted in red. C. LD between the markers used in
the cross-phenotype analyses, and the markers associated with cognitive traits in our previous study [16]. LD is displayed using a r2 scale ranging
from r2 = 1 in black to r2 = 0 in white.
doi:10.1371/journal.pone.0035424.g001
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Markers showing association were selected for extraction of
genotypes from the German GWAS (when available) and for
replication in further samples of BP cases and controls and ADHD
cases and controls. When several markers in strong LD (r2.0.8)
were associated, only one marker was selected for further studies.
The LD is displayed using GOLD Heatmap standards for D9
(blue = 0 to red = 1), and the r2 values are displayed in the relevant
lozenges. In addition the marker rs10507435 was included for its
association with cognitive phenotypes [16].
(TIF)
Table S1 Summary of the data mined in the BP and SCZ
GWASs.
(DOC)
Table S2 Logistic regression analyses and statistics for
the markers extracted from the German GWAS of SCZ.
(DOC)
Table S3 Logistic regression analyses and statistics for
the markers genotyped in the SCZ Scandinavian sample.
(DOC)
Table S4 Logistic regression analyses and statistics for
markers extracted from the German (BoMa) GWAS of
BP.
(DOC)
Table S5 Logistic regression analysis and statistics for
the 20 markers genotyped in the BP replication sample.
(DOC)
Table S6 Logistic regression analyses and statistics for
the 33 markers genotyped in the Norwegian ADHD
sample.
(DOC)
Table S7 Logistic regression analyses and statistics for
the markers extracted from the German ADHD GWAS.
(DOC)
Table S8 Results across samples including the British
GWAS samples for BP (WTCCC) and SCZ (O’Donovan).
(DOC)
Table S9 Regions of high inter-species conservation
around rs7989807.
(DOC)
Table S10 Summary of the genotypes observed for 16
SNPs around rs7989807.
(DOC)
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